Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda includes a drive through the countryside and a get-together with the Pharmalot ancestors. We may also make time for a nap. And what about you? The great outdoors are beckoning, so perhaps this is an opportunity for a hike in the woods or a stroll along a beach. Conversely, you could putter around your castle or catch up on your reading. In other words, treat yourself to a little time and space. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Pfizer (PFE) and the Indian government are at loggerheads over a demand by the drug maker for legal protection from any claims linked to the use of its Covid-19 vaccine, Reuters reports. India has not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including the U.K. and the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.